RxDoctor Payments Data

Laura Crites, PA

Physician Assistant · San Diego, CANPI 1780272591

Payments from drug & device makers

$4,738in general payments, 2019–2025

Across 92 payments — averaging $51.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$813
  • Organon$523
  • Lilly USA, LLC$351
  • Edwards Lifesciences$328
  • Viiv Healthcare Company$289
  • Sanofi$226
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$4,738100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,738 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$29,164
Medicare patients
73
Services billed
648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol16$25,194
MounjaroTirzepatide22$22,988
Losartan Potassium43$641
Pravastatin Sodium18$572
Atorvastatin Calcium58$419
SynthroidLevothyroxine Sodium11$392
Albuterol Sulfate HfaAlbuterol Sulfate18$390
Levothyroxine Sodium33$329
Metoprolol Succinate22$307
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide14$259
Trazodone Hcl25$224
Omeprazole17$198
Metformin Hcl20$162
Lisinopril48$160
Amlodipine Besylate47$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$813$25,19416 claims
Lilly USA, LLCMounjaro$351$22,98822 claims
AbbVieSynthroid$92$39211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →